This article was originally published in The Gray Sheet
Privately-held St. Paul firm expects to launch its Axxess spinal cord stimulation lead in mid-August, following July 16 510(k) clearance. The device is intended for use with radio frequency spinal cord stimulation devices such as Medtronic's X-trel, Mattrix, and DualScreen Screener. Future expansion of the technology could include deep brain stimulation devices, peripheral nerve stimulation devices, and potential cardiac applications, the firm says
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.